Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 5:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,210 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Living Alone Clear all
Completed Phase 3 Interventional

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

NCT01578655
View directory record Official record
Conditions
Prostate Cancer
Interventions
cabazitaxel, prednisone, custirsen sodium
Drug
Lead sponsor
Achieve Life Sciences
Industry
Eligibility
Male only
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
35
States / cities
Marina del Rey, California • Sacramento, California • San Diego, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Jun 10, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients

NCT00533442
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Rapamycin, Mycophenolate Mofetil, Tacrolimus, Steroids
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Jun 10, 2026, 5:10 PM EDT
Completed Not applicable Interventional Results available

Randomized Controlled Trial of a Patient Activation Tool in Pediatric Appendicitis (Antibiotics Alone vs. Appendectomy)

NCT02110485
View directory record Official record
Conditions
Appendicitis, Children
Interventions
Patient Activation Tool
Other
Lead sponsor
Peter Minneci
Other
Eligibility
7 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Jun 10, 2026, 5:10 PM EDT
Recruiting Not applicable Interventional

A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Chronic Non-healing DFUs

NCT07116174
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU)
Interventions
Xcell Amnio Matrix, Standard of Care (SOC)
Biological · Drug
Lead sponsor
New Horizon Medical Solutions
Network
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Fresno, California • San Diego, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jun 10, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Results available

A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy

NCT05261191
View directory record Official record
Conditions
Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1
Interventions
MGD020, MGD014
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
New York, New York • Chapel Hill, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Jun 10, 2026, 5:10 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Can Blood Flow Restriction Therapy Improve Strength for Shoulder External Rotators Better Than Exercise Alone

NCT03815760
View directory record Official record
Conditions
Muscular Weakness
Interventions
Blood Flow Restriction
Device
Lead sponsor
George Fox University
Other
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Newberg, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Jun 10, 2026, 5:10 PM EDT
Terminated Not applicable Interventional

RFA RCT for Pancreatic or Bile Duct Cancer

NCT02166190
View directory record Official record
Conditions
Unresectable Pancreatic Cancer, Cholangiocarcinoma Non-resectable
Interventions
Radiofrequency Ablation using EndoHPB Probe, Stenting only
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Jun 10, 2026, 5:10 PM EDT
Completed Phase 2 Interventional

Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS

NCT00001059
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Doxorubicin hydrochloride (liposomal), Filgrastim, Bleomycin sulfate, Vincristine sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Jun 10, 2026, 5:10 PM EDT
Terminated Phase 1Phase 2 Interventional

A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer

NCT00354562
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell Lung Cancer
Interventions
ABT-751, Placebo, Docetaxel
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
13
States / cities
Birmingham, Alabama • Burbank, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2011 · Synced Jun 10, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects

NCT05226923
View directory record Official record
Conditions
Bacterial Infections
Interventions
KSP-1007, Placebo:0.9% sodium chloride, Meropenem
Drug · Other
Lead sponsor
Sumitovant Biopharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Jun 10, 2026, 5:10 PM EDT
Withdrawn Phase 2 Interventional

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

NCT00615524
View directory record Official record
Conditions
Hormone-receptor Positive Breast Cancer
Interventions
exemestane and pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Jun 10, 2026, 5:10 PM EDT
Terminated Phase 1 Interventional Results available

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

NCT03168438
View directory record Official record
Conditions
Neoplasms
Interventions
Letetresgene autoleucel, Letetresgene autoleucel with pembrolizumab, Fludarabine, Cyclophosphamide, Pembrolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Duarte, California • Miami, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Jun 10, 2026, 5:10 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00019448
View directory record Official record
Conditions
Stage IV Melanoma, Recurrent Melanoma
Interventions
gp100 antigen, interleukin-2
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Timeline
1998 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Jun 10, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults

NCT00382980
View directory record Official record
Conditions
Influenza
Interventions
Aluminum hydroxide, Inactivated Vero cell based whole virus influenza A/H5N1, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
308 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
5
States / cities
Stanford, California • Torrance, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Jun 10, 2026, 5:10 PM EDT
Completed Phase 3 Interventional

A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3

NCT00002123
View directory record Official record
Conditions
HIV Infections
Interventions
Delavirdine mesylate, Didanosine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
14 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
83
States / cities
Birmingham, Alabama • Berkeley, California • Fresno, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

NCT03595059
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ABBV-155, Paclitaxel, Docetaxel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
21
States / cities
Birmingham, Alabama • Springdale, Arkansas • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Jun 10, 2026, 5:10 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Desiccated Thyroid Extract Versus Synthetic T3/T4 Combination (ThyrolarTM) Versus L-T4 Alone in the Therapy of Primary Hypothyroidism With Special Attention to the Gene Polymorphism

NCT02317926
View directory record Official record
Conditions
Hypothyroidism
Interventions
Levothyroxine, Levothyroxine Plus Liothyronine, Desiccated Thyroid Extract
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
1
States / cities
Besthesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Jun 10, 2026, 5:10 PM EDT
Completed Phase 3 Interventional

WelChol® and Insulin in Treating Patients With Type 2 Diabetes

NCT00151749
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Colesevelam hydrochloride
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
45
States / cities
Tuscumbia, Alabama • Sierra Vista, Arizona • Jonesboro, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2012 · Synced Jun 10, 2026, 5:10 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers

NCT03363776
View directory record Official record
Conditions
Cancer
Interventions
BMS-986277, Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jun 10, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas

NCT02740270
View directory record Official record
Conditions
Solid Tumors, Lymphomas
Interventions
GWN323, PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Jun 10, 2026, 5:10 PM EDT
Completed Phase 3 Interventional

Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer

NCT00005966
View directory record Official record
Conditions
Kidney Cancer
Interventions
recombinant interferon alfa, thalidomide
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
11
States / cities
Scottsdale, Arizona • South Bend, Indiana • Des Moines, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2009 · Synced Jun 10, 2026, 5:10 PM EDT
Recruiting Phase 2 Interventional

A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.

NCT07207395
View directory record Official record
Conditions
Lung Cancer (NSCLC)
Interventions
JBI-802, Pembrolizumab
Drug
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Jun 10, 2026, 5:10 PM EDT
Terminated Phase 3 Interventional Results available

Progesterone for the Treatment of Traumatic Brain Injury III

NCT00822900
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Progesterone, Placebo
Drug
Lead sponsor
David Wright
Other
Eligibility
18 Years and older
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tuscon, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Jun 10, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination

NCT02342067
View directory record Official record
Conditions
Healthy
Interventions
Cenicriviroc, Pioglitazone
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Jun 10, 2026, 5:10 PM EDT